{
    "code": "60001179",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001179",
    "time": "2024-03-21 19:43:01",
    "許可證字號": "衛部菌疫輸字第001179號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "115\/12\/07",
    "發證\/登錄日期": "110\/12\/07",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000117901",
    "中文品名": "優赫得凍晶注射劑100毫克",
    "英文品名": "ENHERTU 100 mg powder for concentrate for solution for infusion",
    "適應症": "一、轉移性乳癌\r\n1.\tHER2陽性：單獨使用於具有無法切除或轉移性HER2陽性乳癌，且曾於以下狀況接受過抗HER2療程的成人病人:\r\n(1)\t轉移性癌症治療；或\r\n(2)\t術前或術後輔助治療，且於治療期間或完成治療後 6 個月內癌症復發。\r\n2.\tHER2弱陽性(HER2-low)：單獨使用於具有無法切除或轉移性 HER2弱陽性(IHC 1+或IHC 2+\/ISH-)乳癌，且曾接受過針對轉移性乳癌之化學療法，或在進行輔助化療(adjuvant chemotherapy)期間或完成輔助化療後6個月內癌症復發的成人病人。\r\n二、無法切除或轉移性非小細胞肺癌(NSCLC)：單獨使用於具有無法切除或轉移性非小細胞肺癌(NSCLC)的成人病人，其腫瘤具有活化型HER2(ERBB2)突變，且先前曾接受過全身性治療。\r\n三、局部晚期或轉移性胃癌(GC)：單獨使用於先前曾接受過trastuzumab療程的局部晚期或轉移性HER2陽性胃癌或胃食道接合處(GEJ)腺癌成人病人。",
    "劑型": "243凍晶注射劑",
    "包裝": "100支以下盒裝 100毫克玻璃小瓶裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "基因工程產品_新成分;",
    "監視期限": "115\/12\/07",
    "主成分略述": "trastuzumab deruxtecan",
    "限制項目": "02輸　入 1S須執行確認性療效臨床試驗 5F免除銜接性試驗",
    "申請商名稱": "台灣第一三共股份有限公司",
    "申請商地址": "台北市中山區松江路223號13樓",
    "主製造廠": [
        {
            "製造廠名稱": "BAXTER ONCOLOGY GMBH",
            "製造廠廠址": "KANTSTR. 2, 33790 HALLE\/WESTFALEN, GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "LONZA AG",
            "製造廠廠址": "LONZASTRASSE, CH-3930 VISP, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "DAIICHI SANKYO EUROPE GMBH",
            "製造廠廠址": "LUITPOLDSTRABE 1, D-85276 PFAFFENHOFEN, GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": "二級包裝廠"
        },
        {
            "製造廠名稱": "DAIICHI SANKYO CHEMICAL PHARMA CO., LTD. Onahama Plant",
            "製造廠廠址": "389-4, IZUMIMACHI SHIMOKAWA AZA OTSURUGI, IWAKI, FUKUSHIMA, JAPAN",
            "製造廠公司地址": "",
            "製造廠國別": "JAPAN",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "DAIICHI SANKYO CHEMICAL PHARMA CO., LTD., TATEBAYASHI PLANT",
            "製造廠廠址": "2716-1 AZA KURAKAKE, OAZA AKAIWA, CHIYODA-MACHI, OURA-GUN, GUNMA, 370-0503, JAPAN",
            "製造廠公司地址": "",
            "製造廠國別": "JAPAN",
            "製程": "單株抗體原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000550",
            "成分名稱": "trastuzumab deruxtecan",
            "含量描述": "",
            "含量": "107.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "優赫得凍晶注射劑100毫克_仿單_20211208f-110-12-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001179&Seq=002&Type=9"
        },
        {
            "title": "優赫得100毫克_外盒_20211027-110-12-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001179&Seq=004&Type=8"
        },
        {
            "title": "優赫得100毫克_瓶標_20211027-110-12-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001179&Seq=003&Type=8"
        }
    ]
}